| Ytd | 19.51% | |
| 1y | 62.25% |
| Open | 2.48 | Prev Close | 2.46 | Low | 2.41 | High | 2.52 | Mkt Cap | 323.48M |
| Vol | 0.00 | Avg Vol | 855.56K | EPS | -0.43 | P/E | -5.70 | Forward P/E | -11.84 |
| Beta | 1.12 | Short Ratio | 0.17 | Inst. Own | 11.62% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-12 | 50-d Avg | 2.00 | 200-d Avg | 1.79 | 1yr Est | 7.00 |
IKT News
ADAR1 Capital Management LLC reduced its stake in Inhibikase Therapeutics, Inc. (NASDAQ: IKT) by 18.
WILMINGTON, Del., July 23, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“In
US stock futures up, Nasdaq 100 gains 1%. Danaher Corp (DHR) shares fall 10.1% in pre-market trading
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-s
WILMINGTON, Del., July 14, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“In
WILMINGTON, Del., July 02, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“In
WILMINGTON, Del., May 12, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inh
WILMINGTON, Del., April 07, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“I
WILMINGTON, Del., April 03, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“I
WILMINGTON, Del., March 26, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“I
Inhibikase Therapeutics, Inc. (NASDAQ: IKT - Get Free Report) was the target of a significant increa
Inhibikase Therapeutics (NYSE: IKT - Get Free Report) and Big Cypress Acquisition (OTCMKTS:BCYP - Ge
Inhibikase Therapeutics, Inc. (NASDAQ: IKT - Get Free Report) has been given a consensus recommendat
Big Cypress Acquisition (OTCMKTS:BCYP - Get Free Report) and Inhibikase Therapeutics (NYSE: IKT - Ge
Liminatus Pharma (NASDAQ: LIMN - Get Free Report) and Inhibikase Therapeutics (NASDAQ: IKT - Get Fre
Liminatus Pharma (NASDAQ: LIMN - Get Free Report) and Inhibikase Therapeutics (NASDAQ: IKT - Get Fre
Inhibikase Therapeutics (NASDAQ: IKT - Get Free Report) and Liminatus Pharma (NASDAQ: LIMN - Get Fre
Liminatus Pharma (NASDAQ: LIMN - Get Free Report) and Inhibikase Therapeutics (NASDAQ: IKT - Get Fre
Inhibikase Therapeutics (NASDAQ: IKT - Get Free Report) and Liminatus Pharma (NASDAQ: LIMN - Get Fre
Liminatus Pharma (NASDAQ: LIMN - Get Free Report) and Inhibikase Therapeutics (NASDAQ: IKT - Get Fre
WILMINGTON, Del., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ: IKT) (“In
BOSTON and ATLANTA, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ: IKT) (“
Companies Reporting Before The Bell • CureVac (NASDAQ:CVAC) is likely to report quarterly loss at $
Tuesday saw 132 companies set new 52-week lows.
During Tuesday's session, 275 companies made new 52-week lows.
Companies Reporting Before The Bell • Safe & Green Holdings (NASDAQ:SGBX) is likely to report q
Companies Reporting Before The Bell • Caledonia Mining (AMEX:CMCL) is expected to report earnings f
Upgrades
Companies Reporting Before The Bell • Opiant Pharma (NASDAQ:OPNT) is estimated to report quarterly
During Thursday's session, 97 companies made new 52-week lows.
Gainers
Companies Reporting Before The Bell • Trevena (NASDAQ:TRVN) is likely to report earnings for its
On Wednesday, 348 companies hit new 52-week lows.
During Tuesday's trading, 505 companies set new 52-week lows.
Gainers Splash Beverage Group, Inc. (NYSE: SBEV) shares jumped 70.6% to close at $1.80 on Tuesday
Gainers Universal Security Instruments, Inc. (NYSE: UUU) shares climbed 62.3% to close at $5.00 o
Gainers Universal Security Instruments, Inc. (NYSE: UUU) shares jumped 303.2% to $12.42. DPW Hold